{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Experimental%3A+Primary+Cohort",
    "query": {
      "intervention": "Experimental: Primary Cohort"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 39,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Experimental%3A+Primary+Cohort&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-22T20:01:15.319Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07477639",
      "title": "Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Primary Progressive Multiple Sclerosis",
        "Secondary Progressive Multiple Sclerosis (SPMS)",
        "Multiple Sclerosis",
        "Multiple Sclerosis (MS) Primary Progressive",
        "Multiple Sclerosis (MS) Secondary Progressive"
      ],
      "interventions": [
        {
          "name": "TRX319",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Tr1X, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 39,
      "start_date": "2026-03-01",
      "completion_date": "2029-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-09-22T20:01:15.319Z",
      "location_count": 8,
      "location_summary": "La Jolla, California • Kansas City, Kansas • Rochester, Minnesota + 5 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07477639"
    },
    {
      "nct_id": "NCT05831995",
      "title": "Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "RAS Mutation",
        "RAF Mutation",
        "NF1 Mutation"
      ],
      "interventions": [
        {
          "name": "ABM-168",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ABM Therapeutics Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2023-03-30",
      "completion_date": "2024-06-30",
      "has_results": false,
      "last_update_posted_date": "2024-12-06",
      "last_synced_at": "2026-09-22T20:01:15.319Z",
      "location_count": 6,
      "location_summary": "San Francisco, California • Indianapolis, Indiana • New Brunswick, New Jersey + 3 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Irving",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05831995"
    },
    {
      "nct_id": "NCT00546260",
      "title": "Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myocardial Infarction"
      ],
      "interventions": [
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "PRT060128 Potassium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 70,
      "start_date": "2007-11",
      "completion_date": "2008-07",
      "has_results": true,
      "last_update_posted_date": "2026-06-24",
      "last_synced_at": "2026-09-22T20:01:15.319Z",
      "location_count": 13,
      "location_summary": "Tallahassee, Florida • Des Moines, Iowa • Lexington, Kentucky + 10 more",
      "locations": [
        {
          "city": "Tallahassee",
          "state": "Florida"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Portland",
          "state": "Maine"
        },
        {
          "city": "Takoma Park",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00546260"
    },
    {
      "nct_id": "NCT06120140",
      "title": "Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Amivantamab IV",
          "type": "DRUG"
        },
        {
          "name": "Amivantamab SC",
          "type": "DRUG"
        },
        {
          "name": "Lazertinib",
          "type": "DRUG"
        },
        {
          "name": "Doxycycline",
          "type": "DRUG"
        },
        {
          "name": "Minocycline",
          "type": "DRUG"
        },
        {
          "name": "Clindamycin",
          "type": "DRUG"
        },
        {
          "name": "Chlorhexidine",
          "type": "DRUG"
        },
        {
          "name": "Noncomedogenic skin moisturizer",
          "type": "OTHER"
        },
        {
          "name": "Ruxolitinib",
          "type": "OTHER"
        },
        {
          "name": "Tacrolimus",
          "type": "OTHER"
        },
        {
          "name": "Zinc gluconate",
          "type": "DRUG"
        },
        {
          "name": "Propranolol",
          "type": "DRUG"
        },
        {
          "name": "Timolol",
          "type": "DRUG"
        },
        {
          "name": "Clobetasol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 305,
      "start_date": "2024-02-16",
      "completion_date": "2030-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-09-22T20:01:15.319Z",
      "location_count": 28,
      "location_summary": "Chandler, Arizona • Duarte, California • Fullerton, California + 25 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06120140"
    },
    {
      "nct_id": "NCT03585764",
      "title": "MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "MOv19-BBz CAR T cells",
          "type": "DRUG"
        },
        {
          "name": "Alpha Folate Receptor expression test",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 46,
      "start_date": "2018-10-24",
      "completion_date": "2024-03-26",
      "has_results": true,
      "last_update_posted_date": "2025-03-26",
      "last_synced_at": "2026-09-22T20:01:15.319Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03585764"
    },
    {
      "nct_id": "NCT05774899",
      "title": "CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adenoid Cystic Carcinoma",
        "Metastatic Adenoid Cystic Carcinoma",
        "Recurrent Adenoid Cystic Carcinoma"
      ],
      "interventions": [
        {
          "name": "CB-103",
          "type": "DRUG"
        },
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Michael J. Dennis, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2023-06-01",
      "completion_date": "2028-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-09-22T20:01:15.319Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05774899"
    },
    {
      "nct_id": "NCT07062471",
      "title": "Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Carotid Arteries Prior to Trans-Carotid Stenting (SKYWARD Trans-Carotid IDE [Investigational Device Exemption] Study)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Carotid Artery Calcification",
        "Carotid Artery Diseases"
      ],
      "interventions": [
        {
          "name": "Carotid Intravascular Lithotripsy (IVL)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Shockwave Medical, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 185,
      "start_date": "2026-06-22",
      "completion_date": "2032-10",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-09-22T20:01:15.319Z",
      "location_count": 25,
      "location_summary": "Little Rock, Arkansas • Rancho Mirage, California • Sacramento, California + 20 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07062471"
    },
    {
      "nct_id": "NCT05972720",
      "title": "A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Relapsed/Refractory Large B-cell Lymphoma (LBCL)"
      ],
      "interventions": [
        {
          "name": "Fludarabine (Conditional therapy)",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide Monohydrate (Conditional therapy)",
          "type": "DRUG"
        },
        {
          "name": "firi-cel (Experimental drug)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CARGO Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2023-08-01",
      "completion_date": "2025-04-04",
      "has_results": false,
      "last_update_posted_date": "2025-05-15",
      "last_synced_at": "2026-09-22T20:01:15.319Z",
      "location_count": 31,
      "location_summary": "Little Rock, Arkansas • Duarte, California • Los Angeles, California + 24 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05972720"
    },
    {
      "nct_id": "NCT06843447",
      "title": "A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer Recurrent"
      ],
      "interventions": [
        {
          "name": "Raludotatug Deruxtecan",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rescue Medication",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Pegylated liposomal doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "MK-2010",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 605,
      "start_date": "2025-04-15",
      "completion_date": "2031-02-07",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-09-22T20:01:15.319Z",
      "location_count": 10,
      "location_summary": "New Haven, Connecticut • Louisville, Kentucky • Shreveport, Louisiana + 7 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06843447"
    },
    {
      "nct_id": "NCT05039554",
      "title": "Randomized Trial of ACT and a Care Management App in Primary Care-based Buprenorphine Treatment",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Opioid-use Disorder",
        "Chronic Pain"
      ],
      "interventions": [
        {
          "name": "Acceptance and commitment therapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Valera Smartphone Application",
          "type": "OTHER"
        },
        {
          "name": "Treatment as Usual",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "Albert Einstein College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 125,
      "start_date": "2023-02-02",
      "completion_date": "2027-04-29",
      "has_results": false,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-09-22T20:01:15.319Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05039554"
    }
  ]
}